JBSNF-000088
Based on 12 publication(s) in Google Scholar
JBSNF-000088 (6-Methoxynicotinamide), a analog of nicotinamide (NA), is a potent and orally active Nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 1.8 µM, 2.8 µM, and 5.0 µM for human NNMT, monkey NNMT and mouse NNMT, respectively. JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization, glucose modulation and body weight reduction in animal models of metabolic disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.85%
- CAS No.: 7150-23-4
- Formule: C7H8N2O2
- Masse moléculaire:152.15
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-131042
NNMTiNNMT Inhibitor -
HY-19615
MS023Type I PRMT Inhibitor -
HY-Y0320
Dimethyl sulfoxide, meets analytical specification of Ch.P.Aprotic Solvent -
HY-50876
DaporinadNMPRT Inhibitor -
HY-13259
MG-132Proteasome Inhibitor -
HY-Y1888
Corn oil -
HY-16900
RolipramPDE4 Inhibitor -
HY-15455
RoflumilastPDE4 Inhibitor -
HY-14650
DHEASteroid Hormone -
HY-12495A
ISRIBInhibitor of Integrated Stress Response -
HY-12085
ApremilastPDE-4 Inhibitor -
HY-138300
ALC-0159Liposome
Publications Citing Use of MedChemExpress (MCE) JBSNF-000088
More- Nat Commun. 2025 May 22;16(1):4779. [Abstract]
- Cell Death Discov. 2024 Nov 3;10(1):463. [Abstract]
- Mol Ther Nucleic Acids. 2025 Apr 29;36(2):102548. [Abstract]
- Phenomics. 2026 Aug 21.
- Am J Physiol Cell Physiol. 2025 Mar 1;328(3):C776-C790. [Abstract]
- Am J Physiol Cell Physiol. 2023 Jul 1;325(1):C29-C41. [Abstract]
- Am J Physiol Cell Physiol. 2021 Sep 1;321(3):C585-C595. [Abstract]
- Mol Oncol. 2025 Jul 18. [Abstract]
- J Diabetes Complications. 2025 Jan 18;39(2):108952. [Abstract]
- SSRN. 2026 Jul 16.
- SSRN. 2026 Jun 23.
- Chemosphere. 2021 Jun:273:129727. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
In Vivo Efficacy Study
-
WB
-
Bio/Physico-chemical Assay
Activité biologique
Description
IC50 & Target
IC50: 1.8 µM (human NNMT), 2.8 µM (monkey NNMT) and 5.0 µM (mouse NNMT)[1]
In Vitro
JBSNF-000088 (6-Methoxynicotinamide) has IC50 values are 1.6 and 6.3 μM for U2OS or differentiated 3T3L1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
JBSNF-000088 (50 mg/kg; oral gavage administration; twice daily for four weeks) leads to a statistically significant improvement in oral glucose tolerance on day 28 with glucose tolerance being normalized[1].
JBSNF-000088 (1 mg/kg; intravenous administration; for 4 hours) results in low plasma clearance of 21 mL/min kg and the volume of distribution at steady state of 0.7 L/kg, a very short plasma half-life of 0.5 hours upon intravenous administration[1].
JBSNF-000088 (10 mg/kg; oral gavage; for 4 hours) results in a Cmax of 3568 ng/mL with a Tmax value of 0.5 hours, indicating rapid absorption in the intestine, and half-life of 0.4 hours by oral gavage. The oral bioavailability is found to be approximately 40%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice with high fat diet (HFD)-induced obesity[1]
-
Dosage:50 mg/kg
-
Administration:Oral route of administration for four weeks; oral gavage administration and twice daily for four weeks
-
Result:Showed statistically significant reduction in body weight (%) and led to a statistically significant reduction in fed blood glucose on day 21 by oral route of administration.
Led to a statistically significant improvement in oral glucose tolerance on day 28 with glucose tolerance being normalized by oral gavage administration.
-
Animal Model:C57BL/6 mice[1]
-
Dosage:1 mg/kg (Intravenous administration);10 mg/kg (oral gavage)(Pharmacokinetic Study)
-
Administration:Intravenous administration and oral gavage; for 4 hours
-
Result:Resulted in low plasma clearance of 21 mL/min▪kg and the volume of distribution at steady state of 0.7 L/kg, a very short plasma half-life of 0.5 h upon intravenous administration.
Resulted in a Cmax of 3568 ng/mL with a Tmax value of 0.5 hours, indicating rapid absorption in the intestine, and half-life of 0.4 hours by oral gavage.
Chemical Information
-
CAS No. 7150-23-4
-
Appearance Solid
-
Masse moléculaire 152.15
-
Formule C7H8N2O2
-
Color White to light yellow
-
SMILES
O=C(N)C1=CC=C(OC)N=C1
-
Synonyms
6-Methoxynicotinamide
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
NNMT/1-MNA protects against hepatic ischemia-reperfusion injury through the AKT/FOXO1/ANGPT2/JNK axis. [Abstract]2025 May 22;16(1):4779. PMID: 40404636 -
Cell Death Discov
Overexpressed nicotinamide N‑methyltransferase in endometrial stromal cells induced by macrophages and estradiol contributes to cell proliferation in endometriosis. [Abstract]2024 Nov 3;10(1):463. PMID: 39489776
JBSNF-000088 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Nov 3;10(1):463. [Abstract]
Effect of NNMT inhibitor JBSNF-000088 at 30 μM and 50 μM on migration and invasion of eESCs, evaluated by transwell assay.
JBSNF-000088 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Nov 3;10(1):463. [Abstract]
Representative ectopic lesions harvested on day 21 from control and JBSNF-000088 (10 mg/kg, i.g.)-treated mice, with each column representing an individual mouse.
-
Mol Ther Nucleic Acids
Antisense oligonucleotide targeting nicotinamide N-methyltransferase exhibits antitumor effects. [Abstract]2025 Apr 29;36(2):102548. PMID: 40547843
JBSNF-000088 purchased from MedChemExpress. Usage Cited in: Mol Ther Nucleic Acids. 2025 Apr 29;36(2):102548. [Abstract]
Cell viability in A549 after 2 days of culture in each concentration of FAPI-04-conjugated ASO or JBSNF-000088 (0, 100, 1000 nM).
-
-
Am J Physiol Cell Physiol
Increasing cellular NAD+ protects hepatocytes against palmitate-induced lipotoxicity by preventing PARP-1 inhibition and the mTORC1-p300 pathway activation. [Abstract]2025 Mar 1;328(3):C776-C790. PMID: 39871470 -
Am J Physiol Cell Physiol
Nicotinamide N-methyltransferase (NNMT) upregulation contributes to palmitate-elicited PPARγ transactivation in hepatocytes. [Abstract]2023 Jul 1;325(1):C29-C41. PMID: 37212549 -
Am J Physiol Cell Physiol
Nicotinamide N-methyltransferase upregulation via the mTORC1-ATF4 pathway activation contributes to palmitate-induced lipotoxicity in hepatocytes. [Abstract]2021 Sep 1;321(3):C585-C595. PMID: 34378991
JBSNF-000088 purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2021 Sep 1;321(3):C585-C595. [Abstract]
AML12 cells were treated with either JBSNF-000088 (25 µM) or II399 (25 µM) for 6 h. Total proteins were isolated and PKA substrates detected by Western blotting.
JBSNF-000088 purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2021 Sep 1;321(3):C585-C595. [Abstract]
AML12 cells were pretreated with either JBSNF-000088 (25 µM) or II399 (25 µM) at the presence/absence of PKA inhibitor, either SQ22536 (200 µM) or H89 (10 µM) for 4 h before palmitate exposure for 16 h. Cell death was determined by LDH release.
-
Mol Oncol
Nicotinamide N-methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling. [Abstract]2025 Jul 18. PMID: 40679940 -
J Diabetes Complications
Nicotinamide n-methyltransferase inhibitor synergizes with sodium-glucose cotransporter 2 inhibitor to protect renal tubular epithelium in experimental models of type 2 diabetes mellitus. [Abstract]2025 Jan 18;39(2):108952. PMID: 39848127 -
-
-
Chemosphere
Thiamethoxam induces nonalcoholic fatty liver disease in mice via methionine metabolism disturb via nicotinamide N-methyltransferase overexpression. [Abstract]2021 Jun:273:129727. PMID: 33524747
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (657.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (8.22 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (8.22 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.5723 mL | 32.8617 mL | 65.7233 mL | 164.3083 mL |
| 5 mM | 1.3145 mL | 6.5723 mL | 13.1447 mL | 32.8617 mL | |
| 10 mM | 0.6572 mL | 3.2862 mL | 6.5723 mL | 16.4308 mL | |
| 15 mM | 0.4382 mL | 2.1908 mL | 4.3816 mL | 10.9539 mL | |
| 20 mM | 0.3286 mL | 1.6431 mL | 3.2862 mL | 8.2154 mL | |
| 25 mM | 0.2629 mL | 1.3145 mL | 2.6289 mL | 6.5723 mL | |
| 30 mM | 0.2191 mL | 1.0954 mL | 2.1908 mL | 5.4769 mL | |
| 40 mM | 0.1643 mL | 0.8215 mL | 1.6431 mL | 4.1077 mL | |
| 50 mM | 0.1314 mL | 0.6572 mL | 1.3145 mL | 3.2862 mL | |
| 60 mM | 0.1095 mL | 0.5477 mL | 1.0954 mL | 2.7385 mL | |
| 80 mM | 0.0822 mL | 0.4108 mL | 0.8215 mL | 2.0539 mL | |
| 100 mM | 0.0657 mL | 0.3286 mL | 0.6572 mL | 1.6431 mL |
JBSNF-000088 Related Classifications
HY-112584 Related Classifications
Powered by Bioz